Group items tagged

Wyeth Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted a new "fast track" designation for temsirolimus (CCI-779), an investigational mTOR kinase inhibitor, in the first-line treatment of poor-prognosis patients

Does having enough sunlight and vitamin D give us more power to tolerate gluten and not develop damaging self-destructive auto-antibodies? It's unlikely we'll know in any good RCT (randomized controlled trials). No drug company will put up lettuce $$ to determine that good ol' cheap FREE UVB unblocked-sunshine is going to trump their $2-3/day drug (or super-sized vitamin D analogue) in a head-to-head trial. That's just absurd. And they're not stupid... because they pay staticians a lot of lettuce to figure that out for them.

Now a new and controversial book by an American doctor suggests that taking even higher levels of the vitamin - 10 to 15 times the recommended amounts - can work wonders. Dr James Dowd, who works at the Arthritis Institute of Michigan, has been prescribing vitamin D to people suffering from chronic disorders such as arthritis, back pain and headaches and the result, he claims, is a huge improvement in their symptoms. In his book, The Vitamin D Cure, Dr Dowd describes a number of success stories using this approach. One of his patients, Barbara, for instance, was obese, and suffered from arthritis in one leg as well as high blood pressure. As Dowd explains: "In the past I would have given her anti-inflammatory drugs, pain medication, a pill to lose weight and drug treatment for hypertension."

Evaluation of active hexose correlated compound hepatic metabolism and potential for drug interactions with chemotherapy agents. Mach CM, Fugii H, Wakame K, Smith J. J Soc Integr Oncol. 2008 Summer;6(3):105-9. PMID: 19087767

ScienceDaily (Sep. 9, 2006) - An experimental anti-cancer regimen combined a diuretic, a Parkinson's disease medication and a drug ordinarily used to reverse the effect of sedatives. In research conducted at Washington University School of Medicine in St. Louis, the unusual mixture inhibited the growth of aggressive prostate tumors in laboratory mice.

Drugs, Supplements, and Herbal Information

"Possible effects of berberine, a chemical found in small amounts in goldenseal, include headache, slow heart rate, nausea, vomiting, abdominal bloating, and low white blood cell count. It is not clear if the amount of berberine in goldenseal products is enough to cause these reactions. Toxic doses of berberine may cause seizures or irritation of the esophagus and stomach when taken by mouth. Berberine used intravenously (through the veins) may cause abnormal heart rhythms. Based on laboratory and animal studies, berberine may increase blood concentrations of bilirubin. Berberine theoretically may cause low blood pressure, although a different chemical in goldenseal, hydrastine, may actually cause increased blood pressure. There is limited study of the blood pressure effects of these agents in humans. Based on laboratory and animal studies, the use of goldenseal or berberine could increase the risk of bleeding. However, there are no reliable published reports of bleeding in humans. Caution is advised in patients with bleeding disorders or taking drugs that may increase the risk of bleeding. Dosing adjustments may be necessary. Based on an initial report, goldenseal or berberine may cause increased sun sensitivity, although this is not a commonly reported symptom. Based on laboratory studies, berberine may lower blood sugar. Caution is advised in patients with diabetes or hypoglycemia, and in those taking drugs, herbs, or supplements that affect blood sugar. Serum glucose levels may need to be monitored by a healthcare provider, and medication adjustments may be necessary. "

Research into internal company documents has revealed that Pfizer Inc., the world's largest research-based pharmaceutical company, tampered with the results of at least 16 study reports about its epilepsy drug, Neurontin.

Last week, Harvard researchers reported how healthy 50-year-old men and 60-year-old women could benefit from taking a statin even if they didn't have high cholesterol. The people they studied had high levels of C-reactive protein, or CRP, which is a marker for inflammation. The study showed that risk for major heart problems was cut by about 50 percent among the statin users.\n\nBut like many industry-sponsored drug studies, the results focused on something called "relative risk," which compares differences between study groups. Relative risk has the effect of exaggerating a drug's benefits. What does a 50 percent reduction in heart risk mean? It means that just one out of 120 statin users was helped by the drug.

"Vytorin has struck out again, this time in a clinical trial that compared the drug's safety and efficacy to a prescription form of the B vitamin niacin. The results of the trial, which the New England Journal of Medicine featured in an article and two editorials, were presented Sunday at an American Heart Association meeting and showed that in a direct comparison, niacin worked significantly better than Vytorin and Zetia in reducing arterial blockages. According to a report in NPR, "This study is the third to question whether ezetimibe drugs do what they're supposed to." If lowering LDL or "bad" cholesterol is the doctor's sole intention when prescribing Vytorin to patients, then the drug does a great job. However, as previous studies have shown, lower levels of LDL cholesterol don't automatically translate to cleaner arteries and lower incidences of cardiac arrest. While Vytorin worked better than statins combined with time-release Niacin to lower LDL cholesterol in 200 patients, its performance was inferior in reducing artery clogging deposits."

Coenzyme Q10. Bonakdar RA, Guarneri E. Am Fam Physician. 2005 Sep 15;72(6):1065-70. Review. PMID: 16190504 Coenzyme Q10 is a vitamin-like substance used in the treatment of a variety of disorders primarily related to suboptimal cellular energy metabolism and oxidative injury. Studies supporting the efficacy of coenzyme Q10 appear most promising for neurodegenerative disorders such as Parkinson's disease and certain encephalomyopathies for which coenzyme Q10 has gained orphan drug status. Results in other areas of research, including treatment of congestive heart failure and diabetes, appear to be contradictory or need further clarification before proceeding with recommendations. Coenzyme Q10 appears to be a safe supplement with minimal side effects and low drug interaction potential.

"I like palmitic acid. It causes insulin resistance. Thank goodness. Ted sent me this link. It's depressing. I'm going to discuss a thought drug. I'm going to call it Palmitofake, and it can be developed by Pfizer, no, Fort Dodge. I particularly dislike FD for anaesthesia related reasons. So what does Palmitofake do? BTW, if you didn't need any other hint you can tell this drug is going to bomb as there is neither an x, y or z in its name. Trust FD to screw up (in my mind). Palmitofake is a fluoride substituted analogue of palmitic acid which irreversibly binds to the acyl-CoA interaction site of JNK1 and so inhibits the pathway by which palmitic acid keeps GLUT4 transporters off of the cell surface membrane, whole body-wide. The logic to this is that the lipotoxin, palmitic acid (nature's second biggest mistake, the biggest was obviously cholesterol) can no longer keep glucose out of cells and metabolism can run, unimpaired by fat, for ever on glucose. Woo hoo bring on the glucose."

Refurbished B. Braun Outlook 100 Infusion IV Pump equipped with a color-coded key pad and audible key clicks, the safe, reliable and easy to use Outlook 100 infusion pump provides comprehensive "at-a-glance" viewing of infusion status on a large color display. Designed to help prevent IV medication administration errors, the Outlook 100 Safety Infusion Pump System's extensive customizable DoseGuard™ drug library allows you to configure the pump to match your clinical practice. Hospitals confidently rely on the Outlook 100 Safety Infusion Pump System's: Real-time display of dose limit values during infusion for titration safety Active alphabetic matrix for quick and easy drug selection Proven delivery mechanism provides reliable and accurate operation Air trapping cassette eliminates nuisance alarms Enhanced battery life *Refurbished *1-Year Warranty

Refurbished B. Braun Outlook 100 Infusion IV Pump equipped with a color-coded key pad and audible key clicks, the safe, reliable and easy to use Outlook 100 infusion pump provides comprehensive "at-a-glance" viewing of infusion status on a large color display. Designed to help prevent IV medication administration errors, the Outlook 100 Safety Infusion Pump System's extensive customizable DoseGuard™ drug library allows you to configure the pump to match your clinical practice. Hospitals confidently rely on the Outlook 100 Safety Infusion Pump System's: Real-time display of dose limit values during infusion for titration safety Active alphabetic matrix for quick and easy drug selection Proven delivery mechanism provides reliable and accurate operation Air trapping cassette eliminates nuisance alarms Enhanced battery life *Refurbished *1-Year Warranty

SINGLE USE ONLY. Can be used for reconstituting chemotherapy drugs, antibiotics and other hazardous drugs, designed to prevent aerosolization into the atmosphere.

How chemotherapy takes place? Depending on type of cancer and period of cancer, it stops cancer cells ability of damage and more to divide. Oftenly drugs are used and different for different person. This is systematic therapy also affect your entire body.

Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E, Levine M. Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13604-9. Epub 2005 Sep 12. PMID: 16157892

Indian herbs and herbal drugs used for the treatment of diabetes.\nModak M, Dixit P, Londhe J, Ghaskadbi S, Paul A Devasagayam T.\nJ Clin Biochem Nutr. 2007 May;40(3):163-73.\nPMID: 18398493 \ndoi: 10.3164/jcbn.40.163